Hsp90: A novel target for the disruption of multiple signaling cascades

Current Cancer Drug Targets

Volumn 7, Issue 4, 2007, Pages 369-388

  Bishop, Stephanie C ^a   Burlison, Joseph A ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Cancer; Geldanamycin; Heat shock protein; Hsp90; Inhibitor; Molecular chaperone; Protein folding; Radicicol

Indexed keywords

17 (DIMETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; 17 ALLYLAMINOGELDANAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; CARCINOGEN; CHAPERONE; CISPLATIN; COUMAMYCIN A1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; NOVOBIOCIN; PURINE DERIVATIVE; PYRAZOLE; RADAMIDE HYDROQUINONE; RADANAMYCIN; RADESTER; RADICICOL; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; BIOACCUMULATION; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; FATIGUE; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; METASTASIS; MYALGIA; NAUSEA; NONHUMAN; PANCREATITIS; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW; TUMOR CELL; TUMOR VASCULARIZATION; VOMITING;

HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34249820803     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780809778     Document Type: Review

References (137)

1. Blagg, B. S. J.; Kerr, T. D. Hsp90 Inhibitors: Small Molecules that Transform the Protein Folding Machinery into a Catalyst for Protein Degradation. Med. Res. Rev. 2006, 26, 310-338.
2. Hickey, E. D.; Weber, L. A. Modulation of Heat-Shock Polypeptide Synthesis in HeLa Cells During Hyperthermia and Recovery. Biochemistry 1982, 21, 1513-1521.
3. Buchner, J. Hsp90 & Co. - A holding for folding. TIBS 1999, 24, 136-141.
4. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cellu. Mol. Life Sci. 2002, 59, 1640-1648.
5. Pratt, W. B.; Toft, D. O. Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery. Soc. Exp. Biol. Med. 2003, 111-133.
6. Scheibel, T.; Weikl, T.; Buchner, J. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc. Natl. Acad. Sci. USA 1998, 95, 1495-1499.
7. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82, 488-499.
8. Kim, T.; Jang, C.; Kim, H.; Lee, J.; Ahn, B.; Kim, J. Interaction of Hsp90 with Ribosomal Proteins Protects from Ubiquitination and Proteasome-dependent Degradation. Mol. Biol. Cell 2006, 17, 824-833.
9. Soti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. 2005, 146, 769-780.
10. Hickey, E.; Brandon, S. E.; Smale, G.; Lloyd, D.; Weber, L. A. Sequence and Regulation of a Gene Encoding a Human 89-Kilodalton Heat Shock Protein. Mol. Cell. Biol. 1989, 9, 2615-2626.
11. Zhang, S.; Yu, J.; Cheng, X.; Ding, L.; Heng, F.; Wu, N.; Shen, Y. Regulation of human hsp90a gene expression. FEBS Lett. 1999, 444, 130-135.
12. Sreedhar, A. S.; Kalmar, E.; Csermely, P.; Shen, Y. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004, 562, 11-15.
13. Chen, B.; Piel, W. H.; Gui, L.; Bruford, E.; Monteiro, A. The Hsp90 family of genes in the human genome: Insights into their divergence and evolution. Genomics 2005, 86, 627-637.
14. Shervington, A.; Cruickshanks, N.; Wright, H.; Atkinson-Dell, R.; Lea, R.; Roberts, G. Shervington, L. Glioma: What is the role of c-Myc, hsp90, and telomerase? Mol. Cell. Biol. 2006, 283, 1-9.
15. Buchner, J. S.; Mayr, B. C.; Jakob, U. Purification and characterisation of prokaryotic and eukaryotic Hsp90. Method Enzymol. 1998, 290, 409-418.
16. Yonehara, M.; Minami, Y.; Kawata, Y. Nagai, J.; Yahara, I. Heat-induced Chaperone Activity of HSP90. J. Biol. Chem. 1996, 271, 2641-2645.
17. Schneider, C.; Sepp-Lorenzino, L.; Nimmesgern, E.; Ouerfelli, O.; Danishefsky, S.; Rosen, N.; Hartl, F. U. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA 1996, 93, 14536-14541.
18. Prodromou, C.; Siligardi, G.; O'Brien, R.; Woolfson, D. N.; Regan, L.; Panaretou, B.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain cochaperones. EMBO J. 1999, 18(3), 754-762.
19. Lodish, H.; Berk, A.; Matsudaira, P.; Kaiser, C. A.; Kreiger, M.; Scott, M. P.; Zipursky, S. L.; Darnell, J. Molecular Cell Biology. W.H. Freeman and Company 2003, Edition 5, pp. 71-74.
20. Whitesell, L.; Lindquist, S. L. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
21. Feinberg, A. P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nature 2005, 7, 21-33.
22. Fensterle, J. A trip through the signaling pathways of melanoma. J. Dtsch Dermatol. Ges. 2006, 3, 205-216.
23. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100, 57-70.
24. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent. Cell 1997, 89, 239-250.
25. Richter, K.; Buchner, J. Hsp90: Chaperoning Signal Transduction. J. Cell. Phys. 2001, 188, 281-290.
26. Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochemistry 2000, 351, 289-305.
27. Mayer, M. P.; Bukau, B. Molecular chaperones: The busy life of Hsp90. Curr. Biol. 1999, 9, R322-R325.
28. Koga, F.; Xu, W.; Karpova, T. S.; McNally, J. G.; Baron, R.; Neckers, L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Atk and Erk activation. Proc. Natl. Acad. Sci. USA 2006, 103, 11318-11322.
29. Workman, P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Interact. 2004, 32, 393-396.
30. Premkumar, D. R.; Arnold, B.; Jane, E. P.; Pollack, I. F. Synergistic Interaction between 17-AAG and Phosphatidylinositol 3-Kinase Inhibition in Human Malignant Glioma Cells. Mol. Carcinog. 2006, 45, 47-59.
31. Fujita, N.; Sato, S.; Ishida, A.; Tsuruo, T. Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1. J. Biol. Chem. 2002, 277, 10346-10353.
32. Sherr, C. J.; Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Develop. 1999, 13, 1501-1512.
33. Parry, D.; Mahony, D.; Wills, K.; Lees, E. Cyclin D-CDK Subunit Arrangement is Dependent on the Availability of Competing INK4 and p21 Class Inhibitors. Mol. Cell. Biol. 1999, 19, 1775-1783.
34. Kim, R.; Emi, M.; Tanabe, K.; Murakami, S.; Uchida, Y.; Arihiro, K. Regulation and interplay of apoptotic and non-apoptotic cell death. J. Path. 2006, 208, 319-326.
35. Fortugno, P.; Beltrami, E.; Plescia, J.; Fontana, J.; Pradhan, D.; Marchisio, P. C.; Sessa, W. C.; Alierti, D. C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 2003, 100, 13791-13796.
36. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 2000, 97, 10832-10837.
37. Lindkvist, A. Activity and Regulation of Telomerase in Malignant Cells. Acta Universitatis Upsaliensis Uppsala 2006, Issue 1651-6206, 1-62.
38. Mabuchi, S.; Ohmichi, M.; Kimuar, A.; Hisamoto, K.; Hayakawa, J.; Nishio, Y.; Adachi, K.; Takahashi, H.; Arimoto-Ishida, E.; Nakatsuji, Y.; Tasaka, K.; Murata, Y. Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel. J. Biol. Chem. 2002, 277, 33490-33500.
39. Schulte, T. W.; Blagosklonny, M. V.; Ingui, C.; Neckers, L. Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association. J. Biol. Chem. 1995, 270, 24585-24588.
40. Basso, A. D.; Solit, D. B.; Chiosis, G.; Giri, B.; Tsichlis, P.; Rosen, N. Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function. J. Biol. Chem. 2002, 277, 39858-39866.
41. Sun, Y. p53 and Its Downstream Proteins as Molecular Targets of Cancer. Mol. Carcinog. 2006, 45, 409-415.
42. Walerych, D.; Kudla, G.; Gutkowska, M.; Wawrzynow, B.; Muller, L.; King, F. W.; Helwak, A.; Boros, J.; Zylicz, A.; Zylicz, M. Hsp90 Chaperones Wild-Type p53 Tumor Suppressor Protein. J. Biol. Chem. 2004, 279, 48836-48845.
43. Compton, S. A.; Elmore, L. W.; Haydu, K.; Jackson-Cook, C. K.; Holt, S. E. Induction of Nitric Oxide Synthase-Dependent Telomere Shortening after Functional Inhibition of Hsp90 in Human Tumor Cells. Mol. Cell. Biol. 2006, 26, 1452-1462.
44. Akalin, A.; Elmore, L. W.; Forsythe, H. L.; Amaker, B. A.; McCollum, E. D.; Nelson, P. S.; Ware, J. L.; Holt, S. E. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res. 2001, 61, 4791-4796.
45. Mittal, A.; Pate, M. S.; Wylie, R. C.; Tollefsbol, T. O.; Katiyar, S. K. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int. J. Oncology 2004, 24, 703-710.
46. Keppler, B. R.; Grady, A. T.; Jarstfer, M. B. The Biochemical Role of the Heat Shock Protein 90 Chaperone Complex in Establishing Human Telomerase Activity. J. Biol. Chem. 2005, 281, 19840-19848.
47. Senju, M.; Sueoka, N.; Sato, A.; Iwinaga, K.; Sakao, Y.; Tomimitsu, S.; Tominaga, M.; Irie, K.; Hayashi, S.; Sueoka, E. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J. Cancer Res. Clin. Oncol. 2006, 132, 150-158.
48. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
49. Ali, B. R.; Seabra, M. C. Targeting of Rab GTPases to cellular membranes. Biochemical Society Transactions 2005, 33(Part 4), 652-656.
50. Chen, C. Y.; Balch, W. E. The Hsp90 Chaperone Complex Regulates GDI-dependent Rab Recycling. Molecular Biology of the Cell 2006, 17, 3494-3507.
51. Germano, S.; Barberis, D.; Santoro, M. M.; Penengo, L.; Citri, A.; Yarden, Y.; Gaudino, G. Geldanamycins Trigger a Novel Ron Degradative Pathway, Hampering Oncogenic Signaling. J. Biol. Chem. 2006, 281(31), 21710-21719.
52. Reuter, C. W. M.; Morgan, M. A.; Bergmann, L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000, 96, 1655-1669.
53. Ohji, G.; Hidayat, S.; Nakashima, A.; Tokunaga, C.; Oshiro, N.; Yoshino, K.; Yokono, K.; Kikkawa, U.; Yonezawa, K. Suppression of the mTOR-Raptor Signaling Pathway by the Inhibitor of Heat Shock Protein 90 Geldanamycin. Biochemistry 2006, 139, 129-135.
54. v-src kinase. Proc. Natl. Acad. Sci. USA 1993, 90, 7074-7078.
55. v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328.
56. Arlander, S. J. H.; Felts, S. J.; Wagner, J. M.; Stensgard, B.; Toft, D. O.; Karnitz, L. M. Chaperoning Checkpoint Kinase 1 (Chk1), an Hsp90 Client, with Purified Chaperones. J. Biol. Chem. 2006, 281, 2989-2998.
57. Kunisawa, J.; Shastri, N. Hsp90α Chaperones Large C-Terminally Extended Proteolytic Intermediates in the MHC Class I Antigen Processing Pathway. Immunity 2006, 24, 523-534.
58. Shang, L.; Tomasi, T. B. The Heat Shock Protein 90-CDC37 Chaperone Complex is Required for Signaling by Types I and II Interferons. J. Biol. Chem. 2006, 281, 1876-1884.
59. Becker, B.; Multhoff, G.; Farkas, B.; Wild, P-J, Landthaler, M.; Stolz, W.; Vogt, T. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 2004, 13, 27-32.
60. Hinzpeter, A.; Lipecka, J.; Brouillard, F.; Baudoin-Legros, M.; Dadlez, M.; Edelman, A.; Fritsch, J. Association between Hsp90 and the ClC-2 chloride channel upregulates channel function. Am. J. Physiol. 2006, 290, C45-C56.
61. Jackson, S. E.; Queitsch, C.; Toft, D. Hsp90: from structure to phenotype. Nature Struct. Mol. Biol. 2004, 11, 1152-1155.
62. Oxelmark, E.; Roth, J. M.; Brooks, P. C.; Braunstein, S. E,. Schneider, R. J.; Garabedian, M. J. The Cochaperone p23 Differentially Regulates Estrogen Receptor Target Genes and Promotes Tumor Cell Adhesion and Invasion. Mol. Cell. Biol. 2006, 26, 5205-5213.
63. Krebs, J.; Saremaslani, P.; Caduff, R. ALG-2: a Ca2+-binding modulator protein involved in cell proliferation and in cell death. Biochim. Biophys. Acta 2002, 1600, 68-73.
64. Mollerup, J.; Krogh, T. N.; Nielsen, P. F.; Berchtold, M. W. Properties of the co-chaperone protein p23 erroneously attributed to ALG-2 (apoptotsis-linked gene 2). FEBS Lett. 2003, 555, 478-482.
65. Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J. K.; Singh, S.; Millson, S. H.; Clarke, P. A.; Naaby-Hansen, S.; Stein, R.; Cramer, R.; Mollapour, M.; Workman, P.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1. Mol. Cell 2002, 10, 1307-1318.
66. Barker, C. R.; Hamlett, J.; Pennington, S. R.; Burrows, F.; Lundgren, K.; Lough, R.; Watson, A. J. M.; Jenkins, J. R. The topoisomerase II-Hsp90 complex: A new chemotherapeutic target? Int. J. Cancer 2006, 118, 2685-2693.
67. Barker, C. R.; McNamara, A. V.; Rackstraw, S. A.; Nelson, D. E.; White, M. R.; Watson, A. J. M.; Jenkins, J. R. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res. 2006, 34, 1148-1157.
68. Duvvuri, M.; Konkar, S.; Hong, K.; Blagg, B. S. J.; Krise J. P. A New Approach for Enhancing Differential Selectivity of Drugs to Cancer Cells. J. Am. Chem. Soc. 2006, 1, A-G.
69. Chiosis, G.; Neckers, L. Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive. J. Am. Chem. Soc. 2006, 1, 279-284.
70. Logan, I. R.; Gaughan, L.; McCracken, S. R. C.; Sapountzi, V.; Leung, H. Y.; Robson, C. N. Human PIRH2 Enhances Androgen Receptor Signaling through Inhibition of Histone Deacetylase 1 and Is Overexpressed in Prostate Cancer. Mol. Cell. Biol. 2006, 26, 6502-6510.
71. Richter, K.; Moser, S.; Hagn, F.; Friedrich, R.; Hainzl, O.; Heller, M.; Schlee, S.; Kessler, H.; Reinstein, J.; Buchner, J. Intrinsic Inhibition of the Hsp90 ATPase Activity. J. Biol. Chem. 2006, 281, 11301-11311.
72. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3, 100-108.
73. Scheibel, T.; Weikl, T.; Buchner, J. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc. Natl. Acad. Sci. USA 1998, 95, 1495-1499.
74. Garnier, C.; Lafitte, D.; Tsvetkov, P. O.; Barbier, P.; Leclerc-Devin, J.; Millot, J.; Briand, C.; Makarov, A. A.; Catelli, M. G.; Peyrot, V. Binding of ATP to Heat Shock Protein 90. J. Biol. Chem. 2002, 277, 12208-12214.
75. Nardai, G.; Schnaider, T.; Soti, C.; Ryan, M. T.; Hoj, P. B.; Somogyi, J.; Csermely, P. Characterization of the 90 kDa heat shock protein (Hsp90)-associated ATP/GTPase. J. Biosci. 1996, 21, 179-190.
76. Richter, K.; Muschler, P.; Hainzl, O.; Buchner, J. Coordinated ATP hydrolysis by the Hsp90 Dimer. J. Biol. Chem. 2001, 276, 33689-33696.
77. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S. M.; Panaretou, B.; Piper, P. W.; Pearl, L. H. Structural and Functional Analysis of the Middle Segment of Hsp90: Implications for ATP Hydrolysis and Client Protein and Cochaperone Interactions. Mol. Cell 2003, 11, 647-658.
78. Chadli, A.; Bouhouche, I.; Sullivan, W.; Stensgard, B.; McMahon, N.; Catelli, M. G.; Toft, D. O. Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc. Natl. Acad. Sci. USA 2000, 97, 12524-12529.
79. Terasawa, K.; Minami, M.; Minami, Y. Constantly Updated Knowledge of Hsp90. Biochemistry 2005, 137, 443-447.
80. Chaudhury, S.; Welch, T. R.; Blagg, B. S. J. Hsp90 as a Target for Drug Development. Chem. Med. Chem. 2006, 1, 1331-1340.
81. Schulte, T.; Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279.
82. Lee, D.; Lee, K.; Cai, X.; Dat, N.; Boovanahalli, S. K.; Lee, M.; Shin, J.; Kim, W.; Jeong, J.; Lee, J.; Lee, C.; Lee, J.; Hong, Y.; Lee, J. Biosynthesis of the Heat-Shock Protein 90 Inhibitor Geldanamycin: New Insight into the Formation of the Benzoquinone Moiety. Chembiochem 2006, 7, 246-248.
83. Maroney, A. C.; Marugan, J. J.; Mezzasalma, T. M.; Barnakov, A. N.; Garrabrant, T. A.; Weaner, L. E.; Jones, W. J.; Barnakova, L. A.; Koblish, H. K.; Todd, M. J.; Masucci, J. A.; Deckman, I. C.; Galemmo, Jr.; R. A.; Johnson, D. L. Dihydroquinone Ansamycins: Toward Resolving the Conflict between Low in vitro Affinity and High Cellular Potency of Geldanamycin Derivatives. Biochemistry 2006, 45, 5678-5685.
84. Le Brazidec, J.; Kamal, A.; Busch, D.; Thao, L.; Zhang, L.; Timony, G.; Grecko, R.; Trent, K.; Lough, R.; Salazar, T.; Khan, S.; Burrows, F.; Boehm, M. F. Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90. J. Med. Chem. 2004, 47, 3865-3873.
85. Ge, J.; Normant, E.; Porter, J. R.; Ali, J. A.; Dembski, M. S.; Gao, Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J. R.; Tibbitts, T. T.; Tong, J. K.; Adams, J.; Palombella, V. J. Design, Synthesis, and Biologica Evaluation of Hydroquinone Derivatives of 17-Amino-17- demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90. J. Med. Chem. 2006, 49, 4606-4615.
86. Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier, L, Pak, R. H.; Ali, J. A.; Dembski, M. S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D. S.; Wright, J.; Barrett, J. A.; Palombella, V. J.; Tong, J. K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 2006, 103, 17408-17413.
87. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266.
88. Jez, J. M.; Chen, J. C. -H.; Rastelli, G.; Stroud, R. M.; Santi, D. V. Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90. Chem. Biol. 2003, 10, 361-368.
89. Lee, Y.; Marcu, M. G.; Neckers, L. Quantum Chemical Calculations and Mutational Analysis Suggest Heat Shock Protein 90 Catalyzes Trans-Cis Isomerization of Geldanamycin. Chem. Biol. 2004, 11, 991-998.
90. Moulin, E.; Barluenga, S.; Winssinger, N. Concise Synthesis of Pochonin A, an Hsp90 Inhibitor. Org. Lett. 2005, 7, 5637-5639.
91. Turbyville, T. J.; Wijeratne, E. M. K.; Liu, M. X.; Burns, A. M.; Seliga, C. J.; Luevano, L. A.; David, C. L.; Faeth, S. H.; Whitesell, L.; Gunatilaka, A. A. L. Search for Hsp90 Inhibitors with Potential Anticancer Activity: Isolation and SAR Studies of Radicicol and Monocillin I from Two Plant-Associated Fungi of the Sonoran Desert. J. Nat. Prod. 2006, 69, 178-184.
92. Lampilas, M.; Lett, R. Convergent stereospecific total synthesis of monocillin and monorden (or radicicol). Tetrahedron Lett. 1992, 773-780.
93. Yang, Z.; Geng, X.; Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J. New Efficient Synthesis of Resorcinylic Macrolides via Ynolides: Establishment of Cycloproparadicicol as Synthetically Feasible Preclinical Anticancer Agent Based on Hsp90 as the Target. J. Am. Chem. Soc. 2004, 126, 7881-7889.
94. Cooper, T. S.; Atrash, B.; Sheldrake, P.; Workman, P.; McDonald, E. Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis. Tetrahedron Lett. 2006, 2241-2243.
95. Atrash, B.; Cooper, T. S.; Sheldrake, P.; Workman, P.; McDonald, E. Development of synthetic routes to macrocyclic compounds based on the Hsp90 inhibitor radicicol. Tetrahedron Lett. 2006, 2237-2240.
96. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga S. KF25706, a Novel Oxime Derivative of Radicicol, Exhibits In vivo Antitumor Activity via Selective Depletion of Hsp90 Binding Signaling Molecules. Cancer Res. 1999, 59, 2931-2938.
97. Ikuina, Y.; Amishiro, N.; Miyata, M.; Narumi, H.; Ogawa, H.; Akiyama, T.; Shiotsu, Y.; Akinaga, S.; Murakata, C. Synthesis and Antitumor Activity of Novel O-Carbamoylmethyloxime Derivatives of Radicicol. J. Med. Chem. 2003, 46, 2534-2541.
98. Soga, S.; Sharma, S. V.; Shiotsu, Y.; Shimizu, M.; Tahara, H.; Yamaguchi, K.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Kurebayashi, J.; Schulte, T. W.; Neckers, L. M.; Akinaga, S. Stereospecific Antitumor Activity of Radicicol Oxime Derivatives. Cancer Chemother. Pharmacol. 2001, 48, 435-445.
99. Shen G.; Blagg, B. S. J. Radester, a Novel Inhibitor of the Hsp90 Protein Folding Machinery. Org. Lett. 2005, 7, 2157-2160.
100. He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R. M.; Gewirth, D. T.; Chiosis, G. Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2006, 49, 381-390.
101. Moulin, E.; Zoete, V.; Barluenga, S.; Karplus, M.; Winssinger, N. Design, Synthesis, and Biological Evaluation of HSP90 Inhibitors Based on Conformational Analysis of Radicicol and Its Analogues. J. Amer. Chem. Soc. 2005, 127, 6999-7004.
102. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-Activity Relationships in Purine-Based Inhibitor Binding to Hsp90 Isoforms. Chem. Biol. 2004, 11, 775-785.
103. Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P.; Chiosis, G. Evaluation of 8-Arylsulfanyl, 8-Arylsulfoxyl, and 8-Arylsulfonyl Adenine Derivatives as Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2005, 48, 2892-2905.
104. Biamonte, M. A.; Shi, J.; Hong, K.; Hurst, D. C.; Zhang, L.; Fan, J.; Busch, D. J.; Karjian, P. L.; Maldonado, A. A.; Sensintaffar, J. L.; Yang, Y.; Kamal, A.; Lough, R. E.; Lundgren, K.; Burrows, F. J.; Timony, G. A.; Boehm, M. F.; Kasibhatla, S. R. Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2006, 49, 817-828.
105. Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; McDonald, E.; Hubbard, R. E.; Surgenor, A.; Roughley, S. D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M. J. Novel, Potent, Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based Design. J. Med. Chem. 2005, 48, 4212-4215.
106. Barril, X.; Beswick, M.; Collier, A.; Drysdale, M. J.; Dymock, B. W.; Fink, A.; Grant, K.; Howes, R.; Jordan, A. M.; Massey, A.; Surgenor, A.; Wayne, J.; Workman, P.; Wright, L. 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg. Med. Chem. Lett. 2006, 16, 2543-2548.
107. Barril, X.; Brough, P.; Drysdale, M.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 5187-5191.
108. Dymock, B. W.; Drysdale, M. J.; McDonald, E.; Workman, P. Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Exp. Opin. Ther. Patents 2004, 14, 837-847.
109. Cheung, K. J.; Matthews, T. P.; James, K.; Rowlands, M. G.; Boxall, K. J.; Sharp, S. Y.; Maloney, A.; Roe, S. M.; Prodromou, C.; Pearl, L. H.; Aherne, G. W.; McDonald, E.; Workman, P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3338-3343.
110. Kreusch, A.; Han, S.; Brinker, A.; Zhou, V.; Choi, H.; He, Y.; Lesley, S. A.; Caldwell, J.; Gu, X. Crystal structures of human HSP90a-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 1475-1478.
111. Brough, P. A.; Barril, X.; Beswick, M.; Dymock, B. W.; Drysdale, M. J.; Wright, L.; Grant, K.; Massey, A.; Surgenor, A.; Workman, P. 3-(5-chloro-2, 4-dihydroxyphenyl)-pyrazole-4-carboxamides as novel inhibitors of the Hsp90 molecular chaperone. Bioorg. Med. Chem. Lett. 2005, 15, 5197-5201.
112. Yu, X.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 Inhibitors Identified from a Library of Novobiocin Analogues. J. Amer. Chem. Soc. 2005, 127, 12778-12779.
113. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: Redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J. Amer. Chem. Soc. 2006, 128, 15529-15536.
114. Marcu, M. G.; Chadl, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
115. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins. J. Natl. Cancer Inst. 2000, 92, 242-248.
116. Yun, B.; Huang, W.; Leach, N.; Hartson, S. D.; Matts, R. L. Novobiocin Induces a Distinct Conformation of Hsp90 and Alters Hsp90-Cochaperone-Client Interactions. Biochemistry 2004, 43, 8217-8229.
117. Soti, C.; Vermes, A.; Haystead, T. A. J.; Csermely, P. Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site. Eur. J. Biochem. 2003, 270, 2421-2428.
118. Kanelakis, K. C.; Shewach, D. S.; Pratt, W. B. Nucleotide Binding States of hsp70 and hsp90 during Sequential Steps in the Process of Glucocorticoid Receptor-hsp90 Heterocomplex Assembly. J. Biol. Chem. 2002, 277, 33698-33703.
119. Wegele, H.; Muschler, P.; Bunck, M.; Reinstein, J.; Buchner, J. Dissection of the Contribution of Individual Domains to the ATPase Mechanism of Hsp90. J. Biol. Chem. 2003, 278, 39303-39310.
120. Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90, Evidence that Coumarin Antibiotics Disrupt Hsp90 Dimerization. J. Biol. Chem. 2006, 281, 7161-7171.
121. Burlison, J. A.; Blagg, B. S. J. Synthesis and evaluation of coumermycin A1 Analogues that inhibit the Hsp90 protein folding machinery. Org. Lett. 2006, 8, 4855-4858.
122. Itoh, H.; Ogura, M.; Komatsuda, A.; Wakui, H.; Miura, A. B.; Tashima, Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone Hsp90. Biochemistry 1999, 343, 697-703.
123. Soti, C.; Racz, A.; Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. J. Biol. Chem. 2002, 277, 7066-7075.
124. Mavletova, D. A.; Dvorkin, G. A. Production of Heat Shock Proteins in a Tumor Cell in Response to a Combination of Cisplatin and Heat Shock. Doklady Biochem. Biophys. 2002, 383, 122-124.
125. Palermo, C. M.; Westlake, C. A.; Gasiewicz, T. Epigallocatechin Gallate Inhibits Aryl Hydrocarbon Receptor Gene Transcription through an Indirect Mechanism Involving Binding to a 90 kDa Heat Shock Protein. Biochemistry 2005, 44, 5041-5052.
126. Ohr, L. M. The Novelty of Nutraceuticals. Food Tech. 10.05, 63-66.
127. Goolijarsingh, L. T.; Fernandes, C.; Yan, K.; Zhang, H.; Grooms, M.; Johanson, K.; Sinnamon, R. H.; Kirkpatrick, R. B.; Kerrigan, J.; Lewis, T.; Arnone, M.; King, A. J.; Lai, Z.; Copeland, R. A.; Tummino, P. J. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl. Acad. Sci. USA 2006, 103, 7625-7630.
128. Nowakowski, G. S.; McCollum, A. K.; Ames, M. M.; Mandrekar, S. J.; Reid, J. M.; Adjei, A. A.; Toft, D. O.; Safgren, S. L.; Erlichman, C. A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer. Clin. Cancer Res. 2006, 12, 6087-6093.
129. Ramanathan, R. K.; Trump, D. L.; Eiseman, J. L.; Belani, C. P.; Agarwala, S. S.; Zuhowski, E. G.; Lan, J.; Potter, D. M.; Ivy, S. P.; Ramalingam, S.; Brufsky, A. M.; Wong, M. K. K.; Tutchko, S.; Egorin, M. J. Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17- Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers. Clin. Cancer Res. 2005, 11, 3385-3391.
130. Grem, J. L.; Morrison, G.; Guo, X. -D.; Agnew, E.; Takimoto, C. H.; Thomas, R.; Szabo, E.; Grochow, L.; Grollman, F.; Hamilton, J. M.; Neckers, L.; Wilson, R. H. Phase I and Pharmacologic Study of 17-(Allylamino)-17- Demethoxygeldanamycin in Adult Patients with Solid Tumors. J. Clin. Oncol. 2005, 23, 1885-1893.
131. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase I Pharmacokinetic and Pharamcodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients with Advanced Malignancies. J. Clin. Oncol. 2005, 23, 4152-4161.
132. Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol. Cancer Ther. 2004, 3, 1021-1030.
133. Goetz, M. P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A. A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.; Adjei, A.; Croghan, G.; Erlichman, C. Phase I Trial of 17-Allylamino-17- Demethoxygeldanamycin in Patients with Advanced Cancer. J. Clin. Oncol. 2005, 23, 1078-1087.
134. Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and Its Analogue 17-Allylamino-17-demethoxygeldanamycin Lowers Bcr-Abl Levels and Induces Apoptosis and Differentiation of Bcr-Abl-positive Human Leukemic Blasts. Cancer Res. 2001, 61, 1799-1804.
135. Bagatell, R.; Beliakoff, J.; David, C. L.; Marron, M. T.; Whitesell, L. Hsp90 Inhibitors Deplete Key Anti-Apoptotic Proteins in Pediatric Solid Tumor Cells and Demonstrate Synergistic Anticancer Activity with Cisplatin. Int. J. Cancer 2005, 113, 179-188.
136. Moulick, K.; Clement, C. C.; Aguirre, J.; Kim, J.; Kang, Y.; Felts, S.; Chiosis, G. Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorg. Med. Chem. Lett. 2006, 16, 4515-4518.
137. Avila, C.; Hadden, M. K.; Ma, Z.; Kornilayev, B. A.; Ye, Q.; B. S. J. Blagg. High-throughput screening for Hsp90 ATPase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3005-3008.